Target and Modality
Claudin 18.2 ADC
CD73 Small Molecule
PD-L1/4-1BB Bispecific Antibody
CD24 Monoclonal Antibody
Target Unmet Medical Needs
Claudin 18.2 Expressing tumors
(Claudin 18.2 Low/High Expression Gastric Cancer and Other Solid Tumors)
Checkpoint inhibitor (CPI)-resistant tumors
(Non-small Cell Lung Cancer and Melanoma)
Immune-responsive Tumors (e.g, Melanoma) and "Cold" Tumors
(e.g, Colorectal Cancer)
CD24 Expressing Tumors
(Breast Cancer, Ovarian Cancer, Small Cell Lung Cancer, Non-small Cell Lung Cancer, Liver Cancer, Bladder Cancer, B Cell Lymphoma)
Differentiation
High-affinity antibody allowing the targeting of Claudin 18.2 low expressors
Robust PoC data demonstrated ability in reversing prior anti-PD-1 resistance
Bispecific antibody targeting PD-L1/4-1BB overcoming liver toxicities
Novel macrophage activator targeting CD24 expressing solid tumors